Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 7Stomach Neoplasms 3Adenocarcinoma Of Esophagus 3Uveal Melanoma 2Carcinoma, Hepatocellular 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Urothelial Carcinoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hepatitis B 1Gliosarcoma 1GATA2 Deficiency 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced or Metastatic Solid Malignancies 1Adenocarcinoma of Lung 1

Interventions

relatlimab 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Cystoscopy 1Circulating Tumor DNA 1Cell-Free Nucleic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Muscle Invasive Bladder Urothelial Carcinoma × Nivolumab × Clear all
NCT05987241 2026-05-26

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

National Cancer Institute (NCI)

Phase 2/3 Recruiting
992 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡